BioNano Genomics (BNGO) Gets a Buy from Scotiabank

In a report released today, Sung Ji Nam from Scotiabank maintained a Buy rating on BioNano Genomics (BNGO – Research Report), with a price target of $6.00. The company’s shares closed yesterday at $0.92.

According to TipRanks, Ji Nam is an analyst with an average return of -4.4% and a 44.39% success rate. Ji Nam covers the Healthcare sector, focusing on stocks such as Quanterix, Adaptive Biotechnologies, and Pacific Biosciences.

The word on The Street in general, suggests a Moderate Buy analyst consensus rating for BioNano Genomics with a $4.50 average price target.

BNGO market cap is currently $61.51M and has a P/E ratio of -0.14.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

BioNano Genomics (BNGO) Company Description:

BioNano Genomics, Inc. is a life sciences instrumentation company, which focuses on genome analysis space. The firm engages in the development and marketing of Saphyr system, a platform for ultra-sensitive and ultra-specific structural variation detection that enables researchers and clinicians to accelerate the search for new diagnostics and therapeutic targets and to streamline cytogenetics. The company was founded by Han Cao in October 2003 and is headquartered in San Diego, CA.